中国化学制药股份有限公司成立于1952年，致力于药品及保健食品、特医食品的创新、研发、生产、服务。中国化学制药在中国台湾有6家子公司、中国大陆有2家全资子公司，股票代码：中化1701.

中国化学制药股份有限公司全资子公司--台湾中化健康生技有限公司，负责山东哈维药业的投资业务。台湾中化致力于克弗尔肽全球推广的健康事业，公司团队经过二十年多年研究，发现并验证克弗尔肽在心脑血管、骨科等多领域内具有很好的临床效果。克服了传统开菲尔粒菌种少，胜肽含量极少的难题，通过专利工艺，成功培育出克弗尔肽，填补了国际空白.其技术“新颖抗高血压肽及其用途”，获得包括中国、美国、德国、法国、瑞士等在内的10几个国家和地区的专利。

Founded in 1952, China Chemical Pharmaceutical Co., Ltd. is committed to the innovation, R & D, production and service of medicine, health food and special medical food. Sinochem has 6 subsidiaries in Taiwan and 2 wholly-owned subsidiaries in mainland China, stock code: Sinochem 1701

Taiwan Sinochem Health Biotechnology Co., Ltd. is a wholly-owned subsidiary of China Chemical Pharmaceutical Co., Ltd., which is responsible for the investment business of Shandong Harvey pharmaceutical industry. Taiwan Sinochem  is committed to the global promotion of Kefir Peptide. After more than 20 years of research, the team of the company found and verified thatKefir Peptide has a good clinical effect on cardio cerebrovascular, orthopedic diseases and other fields. The invention overcomes the problem that the traditional kefir granules have few strains and few peptide contents, and successfully cultivates Kefir Peptide through patented technology, which fills the international gap. Its technology "Novel Anti-hypertensive Peptide and its Application" has obtained patents from more than 10 countries and regions including China, the United States, Germany, France, Switzerland,  etc.